Global Next Generation Sequencing (NGS) Data Analysis Industry Market Research 2030

The global next-generation sequencing data analysis market is estimated to be ~USD 600 million by the end of 2021, and it is expected to grow at a compound annual growth rate (CAGR) of ~18% from 2022 to 2030. In the study of epigenome and genomic patterns related to various biological processes. Information storage, management, and access issues are expected to provide potential R&D opportunities for the market, thereby driving market growth. Research groups using high-throughput sequencers need a laboratory information management system (LIMS) to manage and archive sequencing information. The cloud-based platform provides advantageous solutions for computationally intensive tasks during NGS data analysis. Therefore, it has become a quick and easy way to obtain computing resources to perform large-scale NGS data analysis. Therefore, the development of cloud-based bioinformatics platforms and services for large-scale NGS data analysis is expected to rapidly promote the market. BaseSpace, Bina, DNAnexus, LifeScope, GeneSifter and SevenBridges are some of the commercial cloud products. End users can easily use NGS-based tools to analyze sequencing information. The inclusion of the NGS protocol has been specifically used for oncology precision medicine, especially lung and breast cancer. The company also focuses on developing low-cost genome sequencing solutions to improve their business. For example, in February 2020, Nebula Genomics, affiliated with Harvard University, launched a family whole-genome sequencing experiment. This test can read a persons entire genetic code. Product Insights: Services lead the global next-generation sequencing data analysis market, with a revenue share of over 55% in 2020. Profitable NGS data analysis services are easily adopted by organizations that lack the infrastructure required for data management, analysis, and interpretation. Companies, such as ThermoFisher Scientific; Igenbio, Inc; and Toldot Genetics, provide services such as exome interpretation, variant calling, mapping, and annotation. Although the analysis software sector has a low market share in 2020, it is expected to have the fastest compound annual growth rate during the forecast period due to strong demand and increased awareness of sequencing technology. The large amount of data generated through NGS requires management solutions and platforms, resulting in a high demand for such tools and algorithms. The LC Genomics Workbench provided by QIAGEN is one of the data interpretation tools for epigenomics, genomics, metagenomics and transcriptomics in one program. Many companies are committed to providing data processing products, that is, data analysis tools that allow research entities to use NGS for projects. This has driven the growth of the NGS business software sector. Illumina and QIAGEN are the largest data analysis software vendors. Other major players, such as ThermoFisher Scientific, also provide commercial software for NGS data analysis. The Avadis NGS software provided by the company is used together with the Ion PGM system for the management, visualization and analysis of NGS data. Workflow insight: The third-level workflow department will dominate the market in 2020, with a revenue share of over 50%. Various annotation tools are used for NGS level 3 data analysis, and the company is taking strategic steps to expand the scope of these tools. For example, in May 2020, Saphetor SA partnered with Paragon Genomics to develop and commercialize VarSome, a bioinformatics solution for discovering, annotating, and interpreting fast and accurate variants of data generated by NGS. It will be the fastest growing part of the workflow between 2022-2030. The growing application of whole-genome sequencing requires faster secondary analysis tools to meet the growing demand. The implementation of field programmable gate arrays running in the cloud must reduce the time required to perform secondary whole-genome sequencing analysis to expand sample throughput. Field programmable gate arrays are logic circuits with higher efficiency and speed compared with traditional CPUs, and are especially suitable for custom genome analysis. On the other hand, cloud service providers including Amazon Web Services have large data centers that can process a large number of samples at the same time. Model information : The internal model segment has the largest revenue share in 2020, exceeding 60%. The internal model includes companies that use NGS for disease detection and diagnosis, while using the technology and tools in the available software to perform their own analysis. The number of these companies is increasing rapidly. In addition, it is observed that the annual budget for internal data analysis of various academic and research institutions is more than twice that of outsourced data analysis. Internal analysis can also quickly integrate innovative scientific workflows into the bioinformatics process. These factors are most of the reasons for this market segment and are likely to maintain a dominant position during the forecast period. However, over time, the installation of internal data analysis infrastructure requires significant investment and complex IT architecture. The outsourcing model market segment is expected to record the fastest compound annual growth rate from 2022-2030. Taking into account the cost advantages provided by the outsourcing model, companies such as SciBerg provide outsourced NGS data analysis services. However, the adoption rate of outsourcing services by large multinational pharmaceutical and biotech companies is low, which is expected to reduce the revenue of this sector. Read length outlook: Due to the widespread adoption and availability of comparison tools and algorithms for short-read length sequencing data, short-read length sequencing will dominate the global market with a share of 75% in 2020. BaseSpace Sequence Hub is a cloud computing environment for genomics, including a series of short-read sequencing data analysis applications, which can simplify sequencing data management and be used for a wide range of research. Similarly, DRAGEN is a biological IT platform that provides ultra-fast secondary analysis of whole genome, whole exome, and targeted sequencing workflows. In addition, DRAGON also provides a wide range of accelerated secondary analysis pipelines, including comparison pipelines, independent mapping, co-genotyping, methylation and other tools. The market provides profitable opportunities for the long-read and ultra-long-read sequencing segments. Guppy provided by Oxford Nanopore is a set of data processing tools, including bioinformatics post-processing functions and base calling algorithms. Guppys onboard call library is cost-effective because it does not require a stable internet connection or local infrastructure. The toolkit can be integrated with MinKNOW; the device control software provided by Oxford Nanopore; or it can run on Linux, Windows and OS X platforms. End-use insights: Due to the increased adoption of next-generation sequencing data analysis workflows by academic institutions, the academic research department will have the largest revenue share in 2020, exceeding 51%. For example, Wageningen University and Research Center in the Netherlands installed Saphyr systems from Bionano Genomics, Illumina MiSeq, Pacbio Sequel and 10XGenomics Chromium for de novo genome sequencing, resequencing, gene expression analysis (RNA-seq); whole genome . Basic research; and other bioinformatics analysis. Similarly, the University of Pittsburgh established a sequencing, bioinformatics analysis, and high-throughput computing center to assist researchers in ongoing academic research and projects. Western Sydney University (Penrith, Australia) uses Illumina NovaSeq 6000 and Illumina MiSeq to provide sequencing services for its internal students, faculty, and external industry participants and researchers. The clinical research department is expected to record the fastest compound annual growth rate between 2022 and 2030. Research plans that use sequencing technology to develop in vitro tests are expected to affect the growth of clinical research. In addition, with the advent of personalized medicine and assisted diagnosis to monitor disease progression, the demand for NGS data analysis is expected to increase significantly. For example, PierianDx provides Clinical Genomicist Workspace software to provide clinical laboratories with more accurate and optimized analysis and reports. And an explanation of the personalized medical plan. These services are expected to completely change the paradigm of clinical research including clinical trials and drug discovery in the next few years. Regional information: North Americas dominant share in 2020 ihas been 47%. This can be attributed to the existence of a large number of key players, such as Illumina, Thermo Fisher Scientific, Agilent Technologies, and various organizations that integrate analysis software. data. In addition, a large number of NGS research projects are carried out in universities in the United States and Canada, increasing the demand for NGS software tools. In January 2021, Illumina collaborated with Helix to use their sequencing technology to evaluate the new SARS-CoV-2 UK Variant (B.1.1.7) . In the United States, the association also aims to design a national surveillance infrastructure to track new drugs The prevalence and occurrence of strains. The company�s initiatives have driven the demand for Covid-19�s NGS technology, thereby supporting market growth. The Asia-Pacific region is expected to be the fastest-growing regional market from 2021 to 2028. Japan has made significant progress in using sequencing technology to understand the molecular basis of cancer. The Ministry of Health, Labour and Welfare of Japan has approved a number of cancer genomes based on NGS technology for clinical practice. In November 2020, Chung Ho Memorial Hospital of Kaohsiung Medical University in Taiwan cooperated with ACT Genomics to combine the ACT Genomics NGS database with ASUS Smart Cloud services to focus on precision cancer treatment. Major companies and market share information: Illumina and QIAGEN are the two major players in this market. The NGS data analysis software platform provided by QIAGEN is useful at all stages of the workflow. In addition, major companies have acquired smaller companies to strengthen their influence in the market. In June 2020, Illumina completed the acquisition of BlueBee, a cloud software company located in the Netherlands. This acquisition allows the company to improve its ability to analyze and interpret sequencing data. BlueBee cloud capabilities enable Illumina users to flexibly run their custom analyses or access industry products, such as the DRAGEN Bio-IT platform, thereby simplifying data processing and improving operational efficiency. Some of the major players in the next-generation sequencing data analysis market include: Thermo Fisher Scientific, Inc. QIAGENIllumina, Inc. F. Hoffmann-La Roche Ltd. Agilent Technologies, Inc. Bio-Rad Laboratories, Inc. PierianDxIntrexon Bioinformatics Germany GmbH Partk, Inc . Eurofins Scientific Pacific Biosciences of California, Inc. DNASTAR, Inc. Congenica Ltd. Factory Genomics, Inc. Genuity Science DNAnexus Inc. SciGenom Labs Pvt. Ltd. Golden Helix, Inc. Market segments covered by the report: The report forecasts global, regional and national revenue growth, and analyzes the latest industry trends in each market segment from 2022-2030. For the purpose of this research, Kenneth Research has subdivided the next global market segment based on product, workflow, mode, read length, end use, and region. Generating sequencing data analysis market report: Product Outlook (Revenue, 100 Ten thousand dollars, 2022-2030) Service NGS commercial software OS/UIA platform analysis software alignment tools and software DNA sequence alignment RNA sequence alignment protein sequence alignment preprocessing and quality control tools Other workflow perspectives (revenue, millions of dollars, 2022-2030) . Primary and secondary read allocation variant comparison and variant call Terci Arias Annotating Variants Application Specific Sequencing Build Build Sequencing Hole Sequencing, 2022-2030) Internal Read Length Outlook (Revenue, USD Million, 2022-2030) Short Read Long Read Very Long Read End Use Outlook (Revenues, Million USD, 2022-2030) Academic research Clinical research hospitals and clinics Pharmaceutical and biotechnology entities Other users

Geography Analysis:

The report further discusses the market opportunity, compound annual growth rate (CAGR) growth rate, competition, new technology innovations, market players analysis, government guidelines, export and import (EXIM) analysis, historical revenues, future forecasts etc. in the following regions and/or countries:

• North America (U.S. & Canada) Market Size, Y-O-Y Growth, Market Players Analysis & Opportunity Outlook
• Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
• Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC(Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market Size, Y-O-Y Growth Market Players Analys  & Opportunity Outlook
• Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
• Middle East and Africa  (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market Size, Y-O-Y Growth Market Players Analysis & Opportunity Outlook

.